Solid tumors are formed due to aggregation of a group of abnormal tissues that do not comprise of any cyst or liquid areas within. Solid tumors can be of both types, i.e. benign (non-cancerous) as well as malignant (cancerous) in nature. Solid tumors majorly comprise of lymphomas, carcinomas, sarcomas and melanomas; whereas, all forms of leukemias usually do not cause solid tumor formation. The treatment of these solid tumors is a complex task and it requires coordinated actions of many healthcare professionals, such as, radiologists, surgeons, oncologists, radiation specialists, nurses and other professionals. Hence, most of the solid tumors are treated via radiotherapy, chemotherapy and/or surgery. However, at present, surgery is the most preferred choice of treatment for cancerous solid tumors. Chemotherapy is often utilized along with other modes of solid tumor treatment i.e. radiation and/or surgery. Several chemotherapeutic drugs are available along with a ripe pipeline of drugs that will soon be commercialized in the global market. Solid tumor market can be classified into five major segments, based on the site of origin, namely, prostrate cancer, ovarian cancer, bladder cancer, pancreatic cancer and other cancers.
Some of the major driving factors for the growth of this market include increasing incidences of several cases of solid tumors, rising prevalence of different forms of metastatic cancers, increasing demand for highly effective chemotherapeutic agents and ripe pipeline of drugs which is available in the global market. According to World Health Organization (WHO), approximately 8.2 million people died due to different types of cancers worldwide in 2012. Among them lung, colorectal, breast and liver cancers were among the leading causes of cancer deaths. Most common forms of solid tumors include brain tumors (medulloblastoma and glioma) and neuroblastoma; other less common solid tumors include rhabdomyosarcoma and osteosarcoma.
Some of the major drugs that available in the global market are Avastin (bevacizumab), Afinitor (everolimus), Jevtana (cabazitaxel), Sutent (sunitinib), Tarceva (erlotinib), Taxotere (docetaxel), Zytiga (abiraterone acetate), Carboplatin, Cisplatin, Doxorubicin, Gemcitabine and Paclitaxel among others. Also, major promising drugs that are in different stages of clinical trials include Abraxane (albumin-bound paclitaxel), AMG 386 (trebananib), Votrient (pazopanib) and Xtandi (enzalutamide) among others. These drugs will soon be commercialized in the global market, which will further boost this market in future.
Geographically, North America holds the leading position in solid tumor market followed by Europe. Major factors responsible for their dominance in this market include high incidence rate of various solid tumor cases along with very well developed healthcare infrastructure of these regions. These regions also comprise of high geriatric population, which contribute heavily towards the solid tumor patient population in the region. However, Asia Pacific is considered to be the most lucrative market for solid tumor market due to recent advancements in healthcare infrastructure and growing medical tourism in these regions. The region also accounts for high cancer patient population and increasing awareness and affordability of the people of this region will contribute heavily towards the future growth of this market in the region.
Some of the major players operating in this market are AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.